Not medical advice. AOD-9604 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
AOD-9604 is listed in our catalogue under “Healing / Recovery.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
AOD-9604, tyrosine-modified C-terminal HGH fragment (177-191) with β3-adrenergic receptor-mediated lipolysis and GRAS safety designation.
Peer-reviewed literature typically discusses AOD-9604 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Compounds in this family are frequently studied in models of tissue injury, wound closure, and how cells reorganise after damage. Research looks at cell movement, blood-vessel support, and inflammatory balance -not at replacing medical care.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 250–500 mcg subcutaneously · Once daily, administered fasted · Serum t½ ≈ 3–4 min (rapid amino-terminal truncation cascade); primary metabolites (-2aa, -3aa) retain partial anti-lipogenic activity; ~40% oral bioavailability in pigs; clinical trial oral doses: 0.25–1 mg/day. Metabolic effects persist beyond peptide clearance. NOAEL: 100 mg/kg/day (rats), 50 mg/kg/day (cynomolgus monkeys).
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
AOD-9604 is a synthetic, tyrosine-modified version of the C-terminal lipolytic fragment of human growth hormone (Tyr-hGH 177-191) — closely related to native HGH Fragment 176-191, with an added N-terminal tyrosine for stability and lipolytic potency. It was developed to target fat metabolism without the growth or IGF-1 effects of full HGH, and reached Phase 2b human obesity trials. Supplied as a lyophilised research-grade powder for laboratory use only.
In research models AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis via a β3-adrenergic-linked mechanism, reportedly without raising IGF-1 or affecting blood glucose the way full HGH does. These are findings in cell and animal models; New-U supplies it for laboratory research only and implies no human effect.
Early and animal research showed lipolytic activity, but the Phase 2b human obesity trial did not produce statistically significant weight loss versus placebo. So its real-world efficacy is unproven, and it is sold as a research compound only — not an approved weight-loss drug.
For laboratory preparation, dissolve the lyophilised powder in bacteriostatic water: concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added. Keep the reconstituted vial refrigerated at 1–6 °C and protected from light. This is preparation math only; New-U provides no human-use dosing guidance.
AOD-9604 is the same lipolytic fragment with a tyrosine substituted for the N-terminal phenylalanine. The tyrosine substitution improves stability and lipolytic potency and was the design choice that enabled the molecule to progress through formal clinical trials as a distinct research entity.
No - and this was a deliberate design goal. AOD-9604 does not bind the growth hormone receptor, so it does not trigger hepatic IGF-1 synthesis and does not produce the counter-regulatory insulin-opposing effects of full-length HGH. Clinical trials confirmed unchanged glycemic parameters.
The Phase 2b was an oral-dosing study at 0.25-1 mg/day, and those doses were likely too low to produce meaningful weight loss in humans - the earlier Phase 2a at different dosing had shown ~2.6 kg loss versus 0.8 kg placebo. The failure ended commercial development but did not change the preclinical mechanism data.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The disulfide-containing cyclic structure is reasonably stable but plan usage within the normal peptide-handling window.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside AOD-9604.
Primary literature and registries for AOD-9604, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: AOD9604, Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, HGH Fragment Tyrosine Variant, Metabolic Pharmaceuticals AOD